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Abstract 
Background: Systemic inflammation is linked to cardiovascular risk, but the influence of persistent pathogens, 
which are conventionally dichotomously categorized, on circulating levels of inflammatory markers is not clear. 
Antibody levels of pathogens have not been examined in relation to inflammation. 
Methods: Using data from a subsample of the Multi-Ethnic Study of Atherosclerosis, we examined circulating 
levels of interleukin-6 (IL-6), C-reactive protein (CRP) and fibrinogen in relation to five common persistent 
pathogens: cytomegalovirus, herpes simplex virus-1, Hepatitis A virus, Helicobacter pylori and Chlamydia 
pneumoniae. We tested the hypothesis that the number of seropositive pathogens (based on conventional cut-off 
points) would not be as sensitive a marker of inflammation as immune response measured by antibody levels to 
pathogens. 
Results: High antibody response to multiple pathogens showed graded and significant associations with IL-6 (p < 
0.001), CRP (p = 0.04) and fibrinogen (p = 0.001), whereas seropositive pathogen burden did not. In multiple linear 
regression models, high antibody response to multiple pathogens maintained a positive association only with IL-6 
(4.4% per pathogen exhibiting high antibody response, 95% CI 0.0-8.9). 
Conclusions: High antibody response to pathogens was a more consistent marker of inflammatory outcomes 
compared to seropositivity alone and high antibody response to multiple pathogens was a stronger marker 
compared to any single pathogen. 
Background 
Persistent pathogens, those acquired early in life and 
maintained without causing obvious illness, are impli­
cated in cardiovascular disease etiology. Numerous stu­
dies have suggested that persistent viruses such as 
cytomegalovirus (CMV), herpes simplex virus-1 (HSV), 
Hepatitis A virus (HAV) and bacterial pathogens such 
as Helicobacter pylori (H. pylori) and  Chlamydia pneu­
moniae (C. pneumoniae) are associated with cardiovas­
cular disease [1-4], although some studies do not 
support a significant relationship [5-7]. Effects of 
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multiple infectious agents may be synergistic, and some 
authors suggest that pathogen burden (total number of 
pathogens) has a greater impact on cardiovascular risk 
than isolated pathogens [4,8,9]. It is hypothesized that 
the association between pathogens and cardiovascular 
disease is, in part, mediated through chronic activation 
of inflammatory pathways [10,11]. 
In parallel to work linking chronic infections to ather­
osclerosis, a number of studies have shown that various 
markers of systemic inflammation are linked to cardio­
vascular risk. Cytokines such as interleukin-6 (IL-6) 
induce the production and secretion of acute-phase pro­
teins including C-reactive protein (CRP) and fibrinogen 
[12,13]. Chronic activation of these inflammatory path­
ways is hypothesized to promote atherogenesis and 
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thrombosis [14]. Levels of IL-6 [15,16], CRP [17-19] and 
fibrinogen [20] show consistent associations with inci­
dent coronary events and subclinical disease indepen­
dent of established cardiovascular risk factors. A 
number of risk factors for chronic inflammation (includ­
ing smoking [21], physical activity [22], and obesity [23]) 
have been identified. However, the influence of persis­
tent pathogens on circulating levels of inflammatory 
markers is unclear and existing studies have been incon­
sistent [24-26]. 
We used data from a large population-based sample to 
examine associations between infectious agents and 
inflammatory pathways implicated in cardiovascular dis­
ease in healthy adults. We examined circulating levels of 
IL-6, CRP and fibrinogen in relation to the presence of 
and antibody response to five pathogens: CMV, HSV,  
HAV, H. pylori and C. pneumoniae. We hypothesized  
that the conventional definition of pathogen burden 
(number of seropositive pathogens using conventional 
cut-off points) would not be as sensitive a marker of 
inflammation as an alternative definition also taking into 
account antibody levels of pathogens. 
Methods 
Study sample 
The Multi-Ethnic Study of Atherosclerosis (MESA) is a 
population-based longitudinal study designed to investi­
gate risk factors for atherogenesis. Study participants 
(n = 6814), aged 45 to 84 years, were recruited from six 
US communities and were free of clinical cardiovascular 
disease at the time of the baseline visit from July 2000 
to September 2002. The current cross-sectional analysis 
uses data on C. pneumonia from the total cohort at 
baseline, and from a sub-sample of 1000 randomly 
selected cohort members who underwent serum testing 
for additional pathogens implicated in cardiovascular 
disease (CMV, HSV, HAV and H. pylori). Complete 
information including data on all infectious agents, 
inflammatory markers and covariables was available for 
999 individuals. The Institutional Review Board at each 
participating site reviewed the study and written 
informed consent was collected from all participants. 
Detailed methods and aims of the MESA cohort are 
available [27]. 
Data 
During  the baseline visit, a range of  sociodemographic,  
behavioral and anthropometric variables were collected. 
Data included education categorized into four groups 
(less than high school, high school diploma or equiva­
lent, some college or technical school and college 
diploma); body mass index (BMI, kg/m2) to define over­
weight or obesity status as ≥ 25 kg/m2; current alcohol 
intake; pack-years of cigarette smoking, current use of 
medications known to alter inflammatory levels (any 
one or more of the hormone replacement therapies, 
aspirin, oral anti-inflammatory agents, lipid-lowering 
drugs and non-steroidal anti-inflammatory drugs, 
grouped into a single dichotomous variable); and self-
rated health measured on a scale of 1 (best) to 5 
(worst); 1-3 were considered “good self-rated health”. 
Lab tests 
Serum IgG antibodies to CMV, HSV, and H. pylori, 
were measured by indirect enzyme immunoassay using 
commercially available kits (DiaMedex Corp. Miami, 
FL). The sensitivity and specificity of the tests ranged 
from 94-100%. Hepatitis A antibody was measured 
using the IMx HAVAB qualitative microparticle enzyme 
immunoassay (Abbott Laboratories, Abbott Park, IL). 
Immunoglobulin G antibodies to C. pneumoniae were 
detected using a microimmunoflourescent antibody 
assay with a range of 0-4 Microimmunofluorescence 
(MIF) units (Focus Technologies, Cypress, CA). Conven­
tional cut-off points were used to define dichotomous 
seropositivity; equivocal values were classified as posi­
tive. Individuals were considered seropositive for CMV 
infection above 10.0 EU/mL, HSV infection above 16.0 
EU/mL, HAV below a standardized calibrated rate, and 
H. pylori infection above 0.90 EU/mL [28]. Infection 
with C. pneumoniae was considered positive at 1 MIF 
unit or higher. We defined ‘high antibody response’ to 
pathogens as IgG values in the top quartile (lowest 
quartile for HAV). For C. pneumoniae, titer  groups  3-4  
were considered high antibody response. 
Interleukin-6 (pg/mL) was measured by ultrasensitive 
ELISA (R&D Systems, Minneapolis, MN). CRP  (mg/L)  
and fibrinogen (mg/dL) were assessed by nephelometry 
(BNII nephelometer, Dade Behring, Deerfield, IL). Ana­
lytic coefficients of variation were 6.3%, 2.6%, and 3.6% 
for IL-6, fibrinogen, and CRP, respectively. 
Statistical methods 
Descriptive analyses were carried out using chi-squared 
tests (for trend where applicable). Kruskal-Wallis rank 
tests were performed for descriptive variables with 
skewed distributions. The dependent variables were cir­
culating levels of IL-6 in pg/mL, CRP in mg/L and fibri­
nogen in mg/dL. Interleukin-6 and CRP presented 
skewed distributions and were log-normalized prior to 
analysis. Independent variables took two forms: 1) sero­
positive pathogen burden, defined as the count sum of 
seropositive pathogens using conventional cut-off points 
(0-5 pathogens with groups 0-1 collapsed for some ana­
lyses); and 2) high antibody response to multiple patho­
gens, defined as the count sum of pathogens with 
antibody response in the highest quartile (high antibody 
response to 0-5 pathogens, groups 3-5 collapsed for 
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some analyses). We first examined associations of inter­
leukin-6 (IL-6), C-reactive protein (CRP) and fibrinogen 
with dichotomous measures of high antibody response 
to each pathogen and second, with the number of 
pathogens for which there was a high response (0-5). 
We performed the same analysis using conventional 
cut-offs for seropositivity to each pathogen and the 
number of seropositive pathogens. 
Tetrachoric (for dichotomous variables) correlation 
coefficients were calculated to investigate correlations 
between the different dependent variables and one-way 
ANOVA was used to test for differences in inflamma­
tory levels according to levels of markers. Linear regres­
sion was used to estimate adjusted associations of 
seropositivity and high antibody levels with inflamma­
tory markers. Four levels of covariate adjustment were 
used in regression models: 1) adjusted for age and sex; 
2) adjusted for age, sex and race/ethnicity; 3) adjusted 
for age, sex, race/ethnicity and education; and 4) adjusted 
for all of the above plus body mass index, current 
alcohol intake, cigarette smoking (pack-years), diabetes, 
current use of medication and self-rated health. 
Results 
The mean age of the sample was 59 years (range 44-84), 
with 46% white, 21% black, 23% Hispanic and 10% 
Chinese. Women comprised 57% of the sample. Eighteen 
percent had finished high school but had no college edu­
cation and 29% and 37% of participants had some college 
education or completed college, respectively. Mean (SD) 
BMI was 28.6 kg/m2 (5.6) and  72% were overweight or  
obese. Almost 90% rated their health as good. 
Nearly 77% of the sample was seropositive for CMV, 
85% for HSV, 58% for HAV, 46% for H. pylori, and 71% 
for C. pneumoniae. Less than 2% of the sample was 
negative for all five of the tested pathogens, whereas 
51% were seropositive for either four or five. Tetrachoric 
correlation coefficients for seropositivity among patho­
gens ranged between 0.42-0.55 except for those invol­
ving C. pneumoniae, which were weaker and on the 
order of 0.12-0.24. All were statistically significant at the 
p < 0.05 level. Median (IQR) levels for IL-6, CRP, and 
fibrinogen were 1.12 pg/mL (0.72-1.74), 2.00 mg/L 
(0.82-4.59), and 340 mg/dL (296-391), respectively. 
Table 1 shows the distribution of sociodemographic 
and health characteristics of the 999-participant sample 
according to number of seropositive pathogens. There 
was a positive trend of increasing age by number of 
pathogens. Non-whites and less educated individuals 
had higher seropositive pathogen burden (both p < 
0.001). Alcohol consumption was associated with lower 
seropositive pathogen burden, as was self-rated good 
Table 1 Mean (SD) or percent sociodemographic and health characteristics according to seropositive pathogen burden 
in a sub-sample of the Multi-Ethnic Study of Atherosclerosis (2000-2002) 
Number of seropositive pathogens P value* 
0-1 2 3 4 5 
Age, y 56.8 (8.4) 59.1 (9.7) 59.5 (10.0) 59.9 (10.1) 59.9 (9.6) 0.02 
Female 54.6 54.6 58.5 59.4 56.1 0.8 
Race/ethnicity <0.001 
White 21.6 28.8 26.6 14.8 8.3 
Black 2.9 10.1 23.4 34.0 29.7 
Hispanic 1.7 3.9 12.9 35.3 46.1 
Chinese 1.0 1.0 16.2 35.4 46.5 
Education <0.001 
<High school 0.0 1.2 15.1 34.9 48.8 
Finished high school 5.7 11.3 20.3 27.7 35.0 
Some college 8.4 16.8 25.5 26.6 22.7 
College graduate 20.7 25.3 22.6 19.6 12.0 
BMI, kg/m2 28.1 (5.4) 27.9 (5.3) 28.8 (6.1) 28.4 (5.5) 28.6 (5.7) 0.2 
Smoking, pack years 12.2 (30.6) 10.0 (17.1) 18.4 (30.1) 9.8 (18.8) 8.0 (14.4) 0.03 
Alcohol consumer 84.6 73.3 61.8 48.8 44.4 <0.001 
Diabetic 6.4 8.6 7.4 15.6 14.6 0.006 
Self-rated good health 95.4 93.6 90.9 85.1 78.1 <0.001 
N 110 163 217 256 253 – 
Pathogens examined: 
*P-values by chi-squared test. (sex, race/ethnicity, education, alcohol use, diabetes, self-rated health), chi-square test for trend (age and BMI), and Kruskal-Wallis
 
test (pack-years of smoking).
 
BMI: body mass index, kg/m2.
 
Alcohol consumer: alcoholic drink within the past week.
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health, whereas smoking and diabetes were associated 
with a higher pathogen burden. 
Table 2 shows inflammatory marker levels by seropo­
sitivity and level of antibody response to each pathogen. 
Seropositivity for individual pathogens was associated 
with higher inflammatory levels for 11 of the 15 tested 
associations (all except HAV with CRP and fibrinogen; 
H. pylori with CRP; and C. pneumoniae with fibrinogen), 
although only one (HSV with fibrinogen) was significant 
(p = 0.006). HAV infection was significantly associated 
with fibrinogen as well, but inversely. High antibody 
response to multiple pathogens, on the other hand, was 
consistently associated with higher inflammatory levels 
across all markers, although only four (CMV with all 
three markers and C. pneumonia with IL-6) were 
significant. 
Figures 1 and 2 show unadjusted inflammatory levels 
by seropositive pathogen burden and high antibody 
response to multiple pathogens, respectively. Seroposi­
tive pathogen burden was associated with higher circu­
lating levels of IL-6 and fibrinogen but the associations 
were of borderline significance (p = 0.07 and 0.05 for 
Table 2 Inflammatory marker levels by seropositivity and high antibody response to each pathogen in a sub-sample 
of the Multi-Ethnic Study of Atherosclerosis (2000-2002) 
Pathogen Seropositivity* or N IL-6, pg/mL CRP, mg/L Fibrinogen, 
antibody response† mg/dL 
Cytomegalovirus Negative 227 1.07 (1.04) 1.90 (1.08) 345 (75) 
Positive 758 1.18 (1.02) 2.01 (1.05) 349 (73) 
P-value - 0.06 0.5 0.5 
Q1-Q3 510 1.13 (1.03) 1.83 (1.06) 344 (75) 
Q4 249 1.31 (1.04) 2.44 (1.08) 360 (69) 
P-value - 0.004 0.002 0.002 
Herpes simplex virus-1 Negative 150 1.05 (1.05) 1.67 (1.10) 333 (65) 
Positive 835 1.18 (1.02) 2.04 (1.04) 351 (75) 
P-value - 0.05 0.06 0.006 
Q1-Q3 600 1.15 (1.03) 2.02 (1.05) 350 (78) 
Q4 248 1.24 (1.04) 2.09 (1.08) 353 (68) 
P-value - 0.2 0.7 0.4 
Hepatitis A virus Negative 425 1.14 (1.03) 2.02 (1.06) 353 (76) 
Positive 574 1.17 (1.03) 1.95 (1.05) 342 (70) 
P-value - 0.6 0.7 0.02 
Q2-Q4 319 1.13 (1.04) 1.85 (1.07) 348 (73) 
Q1 255 1.21 (1.04) 2.10 (1.08) 357 (79) 
P-value - 0.2 0.2 0.2 
H. pylori Negative 531 1.13 (1.03) 1.99 (1.06) 347 (76) 
Positive 454 1.18 (1.03) 1.97 (1.06) 350 (72) 
P-value - 0.3 0.9 0.5 
Q1-Q3 215 1.17 (1.04) 1.96 (1.09) 347 (69) 
Q4 246 1.20 (1.04) 1.98 (1.08) 352 (74) 
P-value - 0.7 0.9 0.5 
C. pneumoniae Negative 288 1.14 (1.04) 1.90 (1.08) 349 (77) 
Positive 697 1.16 (1.02) 2.02 (1.05) 347 (72) 
P-value - 0.6 0.5 0.7 
T1-T2 534 1.12 (1.03) 1.99 (1.05) 346 (72) 
T3-T4 175 1.32 (1.06) 2.11 (1.11) 353 (72) 
P-value - 0.005 0.6 0.2 
Presented as geometric mean (SE) for IL-6 and CRP; mean (SD) for fibrinogen. 
Q1-Q4 represents lowest through highest quartiles for all pathogens except C. pneumoniae. 
T1-T4 represents titer groups for C. pneumoniae. 
P-values by one-way ANOVA. 
*Cut-offs for seropositive status: cytomegalovirus≥ 8.0 Elisa Units (EU)/mL; herpes simplex virus-1 ≥ 16.0 EU/mL; hepatitis A virus, rate≤ 200; H. pylori≥ 0.90 EU/ 
mL; C. pneumoniae≥ 1.0 Microimmunofluorescence (MIF) units. 
†High antibody response defined as top quartile of antibody response to pathogen (lowest quartile for hepatitis A virus) and titer groups 3-4 for C. pneumoniae. 
Low-intensity defined as bottom three quartiles to pathogens and titer groups 0-2 for C. pneumoniae.. 
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Figure 1 Levels of interleukin-6 (IL-6), C-reactive protein (CRP) and fibrinogen by seropositive pathogen burden in a sub-sample of 
the Multi-Ethnic Study of Atherosclerosis (2000-2002). P values for trend by linear regression. 
trend, respectively). There was no association with CRP. 
The examination of associations of high antibody levels 
with inflammatory markers revealed stronger patterns. 
Levels of IL-6 (p < 0.001), CRP (p = 0.04) and fibrino­
gen (p = 0.001) were all significantly and positively asso­
ciated with high antibody response to multiple 
pathogens. 
Table 3 shows percent differences in inflammatory 
markers associated with both methods of assessing 
pathogen burden; seropositive pathogen burden and 
high antibody response to multiple pathogens, respec­
tively, in four sequentially adjusted models. Positive 
associations between seropositive pathogen burden and 
IL-6 and fibrinogen were modest in model 1 and not 
statistically significant in adjusted models. In contrast, 
high antibody response to multiple pathogens was posi­
tively and significantly associated with IL-6, CRP and 
fibrinogen in model 1, with a 2 to 9% increase in inflam­
matory marker level per pathogen exhibiting a high anti­
body response. Estimates weakened with further 
adjustment, but associations with IL-6 remained statisti­
cally significant after adjustment for age, sex, race/ 
ethnicity, and education (approximately 4% increase per 
pathogen exhibiting a high antibody response; model 3). 
Associations were reduced and no longer statistically 
significant when further adjusted for BMI, behavioral, 
and health variables (model 4). 
Interactions of sex and race with pathogen burden 
(according to seropositivity or high antibody response) 
revealed no consistent patterns. 
Discussion 
This is among the first studies to evaluate the relation­
ship between pathogen burden based on conventional 
cut-offs for seropositivity and high antibody response as 
potential correlates of multiple markers of inflammation. 
We found that high antibody response was a more con­
sistent marker of inflammatory outcomes than seroposi­
tivity alone. Previous work has generally not 
differentiated between seropositivity and antibody 
response [29], but our results suggest that this may be 
an important distinction. Earlier studies showed similar 
associations with inflammation in many of the patho­
gens examined here, suggesting that our results are 
Figure 2 Levels of interleukin-6 (IL-6), C-reactive protein (CRP) and fibrinogen by high antibody response to multiple pathogens in a 
sub-sample of the Multi-Ethnic Study of Atherosclerosis (2000-2002). P values for trend by linear regression. 
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Table 3 Percent difference in inflammatory markers associated with increasing seropositive pathogen burden* and 
increasing number of pathogens exhibiting high antibody response† in a sub-sample of the Multi-Ethnic Study of 
Atherosclerosis (2000-2002) 
Method 
Seropositive pathogen burden* 
Inflammatory marker 
IL-6 
Model 1 
2.2 (-0.9,5.3) 
Model 2 
0.7 (-2.9,4.4) 
Model 3 
-1.4 (-5.0,2.4) 
Model 4 
-2.6 (-6.0,0.9) 
CRP 1.4 (-4.1,7.2) 0.5 (-5.9,7.3) -2.0 (-8.4,4.9) -4.2 (-10.1,2.0) 
High antibody response to multiple pathogens† 
Fibrinogen 
IL-6 
0.7 (-0.3,1.6) 
9.3 (4.9,13.8) 
-1.2 (-2.3,0.0) 
5.8 (1.5,10.3) 
-1.6 (-2.7,-0.5) 
4.4 (0.0,8.9) 
-1.7 (-2.8,-0.6) 
1.7 (-2.4,6.0) 
CRP 8.0 (0.2,16.4) 4.3 (-3.3,12.5) 2.2 (-5.3,10.4) -0.2 (-7.3,7.4) 
Fibrinogen 2.0 (0.7,3.3) 0.7 (-0.6,2.0) 0.4 (-0.9,1.8) 0.2 (-1.1,1.5) 
*Seropositive pathogen burden: seropositivity to 0-5 pathogens analyzed as a continuous variable. 
†High antibody response to multiple pathogens: high antibody response to 0-5 pathogens analyzed as a continuous variable. 
Coefficient (95% CI) shows the percent difference in inflammatory marker level per additional seropositive pathogen or per additional pathogen exhibiting a high
 
antibody response.
 
Model 1 adjusted for age and sex.
 
Model 2 adjusted for age, sex and race/ethnicity.
 
Model 3 adjusted for age, sex, race/ethnicity and education.
 
Model 4 adjusted for all of the above plus body mass index, alcohol intake, smoking (pack years), diabetes, medications, self-rated health.
 
compatible with population based estimates [8,26,30-32]. 
Also in line with previous findings, sociodemographic 
and health indices were significantly associated with 
number of seropositive pathogens [28,33-35]. There are 
less data, however, showing the relationships between 
sociodemographic characteristics and antibody response 
in population based studies in the US. 
Testing of persistent pathogens often relies on enzyme 
linked immunosorbent assays (ELISA). These assays 
provide a qualitative assessment of the amount of anti­
body in a serum sample. Clinical studies are generally 
concerned with whether or not individuals tests positive 
for IgM or IgG to the pathogen of interest and rarely 
provide data on the qualitative antibody response identi­
fied in the ELISA test. Our findings regarding associa­
tions of antibody response with inflammation suggests 
that the qualitative data obtained from an ELISA is an 
important variable given that this measure predicts 
inflammation levels. Our findings suggest that antibody 
levels among the infected, rather than seropositivity is a 
better marker of inflammatory levels. 
Pathogen burden (number of seropositive pathogens) 
was more strongly associated with inflammation than 
was any one individual pathogen and seropositivity to 
pathogens was highly correlated. Pathogen burden has 
been implicated in cardiovascular disease in several dif­
ferent study populations [33,36]. It has been suggested 
that pathogen burden may not only be a predictor of 
coronary complications, as previously described, but that 
it may also be associated directly with the development 
of atherosclerotic plaques [24]. Zhu and colleagues have 
suggested that inflammation is one pathway by which 
these associations are linked [8]. Prasad et al. found that 
pathogen burden and CRP levels interacted significantly 
such that carriers of 4-5 pathogens and elevated CRP 
levels (> 0.5 mg/dL) had higher odds of coronary artery 
disease compared to those with fewer pathogens [4], 
supporting the notion that pathogen burden along with 
inflammation has a stronger impact than any one patho­
gen alone or inflammation alone. A recent study showed 
that antibody levels to one of the pathogens we exam­
ined here, CMV, was associated with an increased rate 
of cardiovascular mortality among aging individuals 
[37]. No previous studies have examined the impact of 
high antibody response to multiple pathogens on inflam­
matory outcomes. 
We found that associations of antibody levels with  
IL-6 were more consistent than associations with the 
other inflammatory markers. In addition, associations 
with IL-6 persisted after adjustment for age, race and 
socioeconomic factors but were reduced and no longer 
statistically significant after adjustment for potential 
mediators of inflammation such as smoking and obesity. 
Limited sample size, as well as strong associations 
between antibody levels and variables such as BMI and 
smoking may have hampered our ability to detect asso­
ciations after multiple adjustments. Larger studies are 
needed to determine whether associations are indepen­
dent of other risk factors. 
There are several possible pathways by which high 
antibody response to multiple pathogens could impact 
inflammation more strongly than seropositivity alone. 
Infection with a particular pathogen may not strongly 
influence a disease process whereas a strong immune 
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response to that pathogen may. Rheumatic heart disease 
is an example of this phenomenon whereby the immune 
response to the pathogen (and ensuing inflammation) is 
the relevant disease process, rather than the infection 
itself [38]. In the case of infections occurring early in 
life and persisting over time (likes several of the patho­
gens we studied); a higher initial infectious dose may 
lead to a more vigorous antibody response at a young 
age which is maintained over the life course for persis­
tent infections. Since persistent infections are generally 
acquired early in life [39], the long term effects of high 
antibody response may lead to chronically higher levels 
of inflammation. However, it is not clear why individuals 
exhibit differentials in antibody response to pathogens. 
Recent work has indicated that lower socioeconomic 
position and exposure to chronic stressors may lead to a 
higher antibody response to CMV, HSV, and H. pylori 
[28,40]. Indeed, there are several experimental studies 
that have demonstrated significant relationships between 
exposure to psychosocial stressors and a high antibody 
response to persistent herpes virus (see Herbert and 
Cohen 1993 for review). Thus, a number of host charac­
teristics may influence antibody response to an infec­
tion. Additional studies are needed to better understand 
the mechanisms by which antibody response may influ­
ence systemic inflammation over the life course. 
Some methodological considerations of this study war­
rant mention. Relatively small sample sizes may have 
affected our ability to detect associations with all mar­
kers. The inflammatory outcomes we tested could have 
been influenced by a number of factors that were not 
measured or measured imprecisely, even though care 
was taken to account for several potentially inflamma­
tory conditions and medications that may impact 
inflammation. Our models also did not account for 
recent or current acute inflammatory states, such as 
those associated with the common cold, which may 
have impacted our findings. Antibody and biomarker 
levels were only measured once and intra-individual var­
iation cannot be accounted for. However, assay variabil­
ity would be expected to bias findings towards the null 
so the observed associations are potentially underestima­
tions. Also, IgG antibody response provides data on past 
infection- we did not examine data on recent infection 
or DNA shedding of the viruses and cannot assess 
whether individuals were experiencing reactivation of 
the infection. The cross-sectional nature of this analysis 
precludes implications of causality, and specifically, we 
cannot rule out the possibility that higher inflammatory 
status may have led to higher levels of antibodies via 
activation of the immune response. Four racial/ethnic 
groups were represented in our data, adding an impor­
tant strength to our study; however, findings may not be 
representative of other ethnic or age groups. Finally, it is 
important to note that viral and bacterial infectious 
agents may act through different mechanistic pathways 
to impact inflammation, but assessment of alternative 
biological pathways, such as infection residing within 
the cardiovasculature, was beyond the scope of this 
cross-sectional observational study. 
Conclusions 
In summary, high antibody response to multiple patho­
gens emerged as a better marker of inflammation com­
pared to seropositivity status alone. Our findings suggest 
that future studies should consider including antibody 
response data in addition to seropositivity classification 
of pathogens. Technological advances for refining mea­
surement of antibody response for persistent pathogens 
is an important endeavor and may reduce measurement 
error in this potentially important biomarker. Opportu­
nities for further research also include examination of 
the mechanistic pathways by which antibody response 
to pathogens contributes to inflammation as well as to 
cardiovascular disease and its correlates. 
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